D
David L. Veenstra
Researcher at University of Washington
Publications - 289
Citations - 18567
David L. Veenstra is an academic researcher from University of Washington. The author has contributed to research in topics: Cost effectiveness & Population. The author has an hindex of 56, co-authored 263 publications receiving 17276 citations. Previous affiliations of David L. Veenstra include University of California, San Francisco & University of California, Berkeley.
Papers
More filters
Journal ArticleDOI
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
Mark J. Rieder,Alexander P. Reiner,Brian F. Gage,Deborah A. Nickerson,Charles S. Eby,Howard L. McLeod,David K. Blough,Kenneth E. Thummel,David L. Veenstra,Allan E. Rettie +9 more
TL;DR: VKORC1 haplotypes can be used to stratify patients into low-, intermediate-, and high-dose warfarin groups and may explain differences in dose requirements among patients of different ancestries.
Journal ArticleDOI
VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Shannon M. Bates,Ian A. Greer,Saskia Middeldorp,David L. Veenstra,Anne-Marie Prabulos,Per Olav Vandvik +5 more
TL;DR: In this article, the authors focused on the management of VTE and thrombophilia as well as the use of antithrombotic agents during pregnancy. But they did not consider the risk of pregnancy complications.
Journal ArticleDOI
Evidence-Based Management of Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Anne Holbrook,Sam Schulman,Daniel M. Witt,Per Olav Vandvik,Jason S. Fish,Michael J. Kovacs,Peter Svensson,David L. Veenstra,Mark Crowther,Gordon H. Guyatt +9 more
TL;DR: In this article, the authors focus on the common important management questions for which, at a minimum, low-quality published evidence is available to guide best practices and provide guidance for many common anticoagulation-related management problems.
Journal ArticleDOI
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
Mitchell K. Higashi,David L. Veenstra,L. Midori Kondo,Ann K. Wittkowsky,Sengkeo L. Srinouanprachanh,Fred M. Farin,Allan E. Rettie +6 more
TL;DR: The results of this study suggest that the CYP2C9*2 and CYP1c9*3 polymorphisms are associated with an increased risk of overanticoagulation and of bleeding events among patients in a warfarin anticoagulated clinic setting, although small numbers in some cases would suggest the need for caution in interpretation.
Journal ArticleDOI
Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin
Brian F. Gage,Charles S. Eby,Julie A. Johnson,Elena Deych,Mark J. Rieder,Paul M. Ridker,Paul E. Milligan,Gloria R. Grice,Petra A. Lenzini,Allan E. Rettie,Christina L. Aquilante,Christina L. Aquilante,Leonard E. Grosso,Sharon Marsh,Taimour Y. Langaee,LE Farnett,Deepak Voora,Deepak Voora,David L. Veenstra,Robert J. Glynn,A Barrett,Howard L. McLeod,Howard L. McLeod +22 more
TL;DR: The goal was to develop and validate a pharmacogenetic algorithm that explained 53–54% of the variability in the warfarin dose in the derivation and validation cohorts.